LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
SANOFI : Berenberg again raises its price target CF
SANOFI : Berenberg gives a Buy rating ZD
European Midday Briefing : Traders Await Presidential Debate, U.S. CPI Print DJ
Berenberg Raises Price Target on Sanofi to EUR115 From EUR105, Maintains Buy Rating MT
SANOFI : Oddo BHF raises its target price on the stock CF
SANOFI : Gradually proving it is right Alphavalue
Veeva Systems: leader in cloud solutions for the life sciences industry Our Logo
ALX Oncology Holdings Inc. Announces First Patients Dosed with Evorpacept and Sarclisa as Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi CI
AlphaValue/Baader Europe Downgrades Sanofi to Add MT
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading MT
SANOFI : Berenberg reiterates buy recommendation, target 105 euros CF
SANOFI : Bernstein gives a Buy rating ZD
SANOFI : Berenberg reaffirms its Buy rating ZD
SANOFI : Deutsche Bank maintains a Sell rating ZD
SANOFI : Stifel raises its target price CF
CAC40: erases losses and ends slightly higher CF
SANOFI : Stifel reiterates its Buy rating ZD
Sanofi: upbeat after MS data CF
SANOFI : JP Morgan remains Neutral ZD
SANOFI : Jefferies reiterates its Buy rating ZD
Europe's STOXX 600 falls ahead of data-intensive week RE
Sanofi's mixed fortunes in MS drug trials has market focus on win RE
Sanofi Multiple Sclerosis Drug Delays Disability Progression in Trial -- Update DJ
SANOFI : Oddo BHF positive after partial success in MS study CF
Sanofi: multiple sclerosis drug tolebrutinib misses primary endpoint in phase III trials RE
Chart Sanofi
More charts
Logo Sanofi
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
Employees
86,088
Calendar
18/09/2024 - UBS Bus Tour
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
105.76EUR
Average target price
111.04EUR
Spread / Average Target
+4.99%
Consensus
  1. Stock Market
  2. Equities
  3. SAN Stock
  4. News Sanofi
  5. Bernstein: Sanofi Set to Record Growth on Expected Multiple Sclerosis Boost
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW